Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity


https://doi.org/10.4081/bse.164
Vol. 2 No. 1 (2021)
Published: 29 September 2021
Drug resistance, ERCC1-XPF, p53, cancer therapy
Abstract views:
398


PDF:
213
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Gloria Ciniero
    gloria.ciniero@polito.it
    PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino, Italy.
  • Francesco Gentile University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB, Canada.
  • Ahmed H. Elmenoufy University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB, Canada.
  • Emeline Cros-Perrial Université Claude Bernard Lyon 1, Lyon, France.
  • Frederick G. West University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB, Canada.
  • Michael Weinfeld University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB, Canada.
  • Marco A. Deriu PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino, Italy.
  • Lars P. Jordheim Université Claude Bernard Lyon 1, Lyon, France.
  • Jack A. Tuszynski PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino, Italy.

New disruptors of the ERCC1-XPF interaction interaction have a synergistic effect with traditional NER inhibitors, in p53 positive cells. Furthermore, the synergy can be resumed in p53 negative cells upon reactivation of the TP53 gene.


[1] Gentile, F, Elmenoufy, AH, Ciniero, G, et al. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein–protein interaction. Chem Biol Drug Des 2020;95:460– 71.
[2] Jordheim LP, Barakat KH, Heinrich-Balard L, et al. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol Pharmacol 2013;84:12-24.
[3] Friboulet L, Soria JC, Olaussen KA. The “Guardian of the Genome”—An Old Key to Unlock the ERCC1 Issue. Clin Cancer Res 2019;25:2369-71.
[4] Ciniero G, Elmenoufy AH, Gentile F, et al. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair. Cancer Chemother Pharmacol 2021;87:259-67.
Ciniero, G., Gentile, F., Elmenoufy, A. H., Cros-Perrial, E. ., West, F. G., Weinfeld, M., Deriu, M. A., Jordheim, L. P., & Tuszynski, J. A. (2021). Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity. Biomedical Science and Engineering, 2(1). https://doi.org/10.4081/bse.164

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC